Summary
2.09 0.07(3.22%)09/13/2024
Longeveron LLC (LGVN)
Longeveron LLC (LGVN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.22 | -6.95 | -18.27 | 10.41 | 336.77 | -17.28 | 0.00 | -72.87 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.09 | |
| Open | 2.05 | |
| High | 2.13 | |
| Low | 2.03 | |
| Volume | 441,886 | |
| Change | 0.07 | |
| Change % | 3.22 | |
| Avg Volume (20 Days) | 551,506 | |
| Volume/Avg Volume (20 Days) Ratio | 0.80 | |
| 52 Week Range | 0.33 - 6.40 | |
| Price vs 52 Week High | -67.42% | |
| Price vs 52 Week Low | 531.82% | |
| Range | -2.90 | |
| Gap Up/Down | -0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 30 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 1.1680 | |
| Earnings Per Share | -0.7500 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | -0.7500 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -6.5015 | |
| Return on asset (TTM) | -0.5007 | |
| Return on equity (TTM) | -1.1178 | |
| Revenue TTM | 2,277,531 | |
| Revenue per share TTM | 0.1190 | |
| Quarterly Revenue Growth (YOY) | -0.8760 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 1,826,270 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 17.6525 | |
| Revenue Enterprise Value | 166.2691 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 4,587,080 | |
| Shares Float | 3,664,469 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 14.77 | |
| Institutions (%) | 8.86 | |
08/26 16:05 EST - globenewswire.com
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
08/14 19:58 EST - seekingalpha.com
Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript
Longeveron, Inc. (NASDAQ:LGVN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, and welcome to Longeveron's 2024 Second Quarter Financial Results Conference Call.
Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript
Longeveron, Inc. (NASDAQ:LGVN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, and welcome to Longeveron's 2024 Second Quarter Financial Results Conference Call.
08/01 16:41 EST - investorplace.com
The Top 3 Small-Cap Stocks to Buy Now: Summer 2024
Small-cap stocks are back in favor. After languishing behind their larger brethren for years, small-cap stocks are roaring ahead as investors rotate into the sector once more.
The Top 3 Small-Cap Stocks to Buy Now: Summer 2024
Small-cap stocks are back in favor. After languishing behind their larger brethren for years, small-cap stocks are roaring ahead as investors rotate into the sector once more.
07/29 09:16 EST - investorplace.com
Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates
Longeveron (NASDAQ: LGVN ) jumped after publishing a press release stating that Phase 2a results for its Alzheimer's treatment met primary endpoints. Lomecel-B is a treatment for mild cases of Alzheimer's disease.
Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates
Longeveron (NASDAQ: LGVN ) jumped after publishing a press release stating that Phase 2a results for its Alzheimer's treatment met primary endpoints. Lomecel-B is a treatment for mild cases of Alzheimer's disease.
07/28 16:51 EST - globenewswire.com
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer's Association International Conf
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer's Association International Conf
07/19 16:05 EST - globenewswire.com
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common stock (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 2,236,026 shares of Class A common stock.
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common stock (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 2,236,026 shares of Class A common stock.
07/18 08:45 EST - globenewswire.com
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common stock (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 2,236,026 shares of Class A common stock.
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common stock (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 2,236,026 shares of Class A common stock.
07/17 10:19 EST - investorplace.com
LGVN Stock Alert: Longeveron Pops 18% on FDA Fast-Track Designation
Longeveron (NASDAQ: LGVN ) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company received fast-track designation for its mild Alzheimer's Disease treatment. This has the Food and Drug Administration (FDA) granting this designation to Lomecel-B.
LGVN Stock Alert: Longeveron Pops 18% on FDA Fast-Track Designation
Longeveron (NASDAQ: LGVN ) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company received fast-track designation for its mild Alzheimer's Disease treatment. This has the Food and Drug Administration (FDA) granting this designation to Lomecel-B.
07/17 06:00 EST - investorplace.com
7 Meme Stocks That Deserve a Fresh Set of Eyes
Meme stocks – you know them as social-media-inspired securities that tend to be speculative. Generally speaking, it's difficult to suggest otherwise.
7 Meme Stocks That Deserve a Fresh Set of Eyes
Meme stocks – you know them as social-media-inspired securities that tend to be speculative. Generally speaking, it's difficult to suggest otherwise.
07/10 11:38 EST - invezz.com
Longeveron stock opened 100% up on Wednesday: explore why
Longeveron Inc (NASDAQ: LGVN) soared 100% on Wednesday after its Lomecel-B received RMAT designation from the Food & Drug Administration. Lomecel-B is the company's investigational treatment for Alzheimer's disease.
Longeveron stock opened 100% up on Wednesday: explore why
Longeveron Inc (NASDAQ: LGVN) soared 100% on Wednesday after its Lomecel-B received RMAT designation from the Food & Drug Administration. Lomecel-B is the company's investigational treatment for Alzheimer's disease.
07/10 11:34 EST - investorplace.com
Why Is Longeveron (LGVN) Stock Up 53% Today?
Longeveron (NASDAQ: LGVN ) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company announced a new designation from the Food and Drug Administration (FDA). This has the FDA granting Longeveron's Lomecel-B the Regenerative Medicine Advanced Therapy (RMAT) designation.
Why Is Longeveron (LGVN) Stock Up 53% Today?
Longeveron (NASDAQ: LGVN ) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company announced a new designation from the Food and Drug Administration (FDA). This has the FDA granting Longeveron's Lomecel-B the Regenerative Medicine Advanced Therapy (RMAT) designation.
07/10 07:30 EST - globenewswire.com
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease
Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease
Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease
07/09 09:00 EST - globenewswire.com
Neha Motwani Elected to Longeveron® Board of Directors
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. “I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors,” said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron.
Neha Motwani Elected to Longeveron® Board of Directors
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. “I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors,” said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron.
07/08 09:00 EST - globenewswire.com
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
06/19 10:30 EST - investorplace.com
3 Penny Stocks Poised to Turn Pocket Change Into a Small Fortune by 2028
Penny stocks are a tripwire for mayhem. They can easily blow up your portfolio.
3 Penny Stocks Poised to Turn Pocket Change Into a Small Fortune by 2028
Penny stocks are a tripwire for mayhem. They can easily blow up your portfolio.
06/18 16:48 EST - globenewswire.com
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The resale of the shares of Class A common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No.
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The resale of the shares of Class A common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No.
06/17 09:00 EST - globenewswire.com
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
06/17 08:38 EST - globenewswire.com
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The resale of the shares of Class A common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No.
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The resale of the shares of Class A common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No.
06/13 09:45 EST - invezz.com
Why has Longeveron stock tripled in two days?
Longeveron Inc (NASDAQ: LGVN) rallied another 50% on Thursday as investors continued to celebrate the positive update of its Lomecel-B study. Why is it significant for Longeveron stock?
Why has Longeveron stock tripled in two days?
Longeveron Inc (NASDAQ: LGVN) rallied another 50% on Thursday as investors continued to celebrate the positive update of its Lomecel-B study. Why is it significant for Longeveron stock?
06/13 08:15 EST - investorplace.com
Why Is Longeveron (LGVN) Stock Up 46% Today?
Longeveron (NASDAQ: LGVN ) stock continues to rally on Thursday as investors celebrate positive trial news from the clinical-stage biotechnology company. The big news that boosted shares of LGVN stock higher was investigator data from a Phase 2 trial of Lomocel-B.
Why Is Longeveron (LGVN) Stock Up 46% Today?
Longeveron (NASDAQ: LGVN ) stock continues to rally on Thursday as investors celebrate positive trial news from the clinical-stage biotechnology company. The big news that boosted shares of LGVN stock higher was investigator data from a Phase 2 trial of Lomocel-B.